ESPERIENZA LAVORATIVA

Transcript

1 F O R M A T O E U R O P E O P E R I L C U R R I C U L U M V I T A E Nome/Cognome SHEILA PIVA ESPERIENZA LAVORATIVA 16/03/2016 Oggi Dirigente Medico ex-primo livello a tempo indeterminato 01/08/ /03/2016 Dirigente Medico ex-primo livello a tempo determinato 11/06/ /10/2012 Incarico di supplenza per dirigente Medico ex-primo livello Novembre 2009 Giugno 2012 e Ottobre Luglio 2013 U.O. Oncologia Medico borsista specialista in oncologia Luglio 2006 Ottobre 2009 Prof. Paolo Corradini U.O. Ematologia e Trapianto di midollo allogenico Medico specializzando Marzo Luglio 2006 Dott.ssa Elena Piazza Ospedale Luigi Sacco - Milano U.O. Oncologia Medico frequentatore ISTRUZIONE E FORMAZIONE Novembre Marzo 2013 Master in Oncologia Toracica Prof. Giorgio Scagliotti, Ospedale San Luigi, Orbassano (TO) Marzo 2012 ESO- ESMO Masterclass In Clinical Oncology Ermatingen, Switzerland Ottobre 2011 Istituto Oncologico della Svizzera Italiana, Bellinzona, Svizzera. ESMO Visita a un Unità di Ricerca Traslazionale Novembre 2009 Università statale degli studi di Milano Oncologia medica

2 Diploma di specializzazione in Oncologia medica Tesi sperimentale: Il trapianto allogenico migliora la sopravvivenza nei pazienti con linfoma di Hodgkin ricaduto dopo trapianto autologo. Luglio 2005 Università degli studi di Milano Medicina e chirurgia Laurea in medicina e chirurgia Tesi sperimentali: Utilità clinica del marcatore Her-2/neu nelle pazienti con carcinoma mammario Cambridge University Certificate of Proficiency in English PUBBLICAZIONI SCIENTIFICHE FULL PAPER Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, Cordovana A, Farina G, Bramati A, Piva S, Dazzani MC, Paternò E, La Verde NM. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One Dec 6;12(12):e doi: /journal.pone ecollection Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Sci Rep Dec 14;6: doi: /srep Rulli E, Marabese M, Piva S, Bonomi L, Caiola E, Ganzinelli M. DNA repair gene polymorphisms in nonsmall-cell lung cancer patients treated with first-line platinum-containing chemotherapy. Tumori Aug 3;102(4): doi: /tj Epub 2016 Jul 7. Ganzinelli M, Rulli E, Caiola E, Chiara Garassino M, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Agnese Fabbri M, Martelli O, Fagnani D, Cristina Locatelli M, Bertolini A, Valmadre G, Pavese I, Calcagno A, Giuseppa Sarobba M, Marabese M. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep Nov 17;5: doi: /srep Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget Oct 20;6(32): doi: /oncotarget Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, Piva S, Dimaiuta M, La Verde N. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with biphosphonates for bone metastases. J Bone Miner Metab Jan;33(1): doi: /s x. Epub 2014 Feb 20. Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, Moretti A, Dazzani MC, Sburlati P, La Verde N. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev Jun;40(5): doi: /j.ctrv Epub 2014 Feb 4. Review. La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, Piva S, Di Maio M. Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncol Dec;9(12): doi: /fon La Verde N, Piva S, Ganzinelli M, Farina G, Gherardi G, Girelli S, Bramati A, Del Re L, Damia G. Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin. Future Oncol Nov;9(11): doi: /fon

3 Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggini M, Marabese M. Across The Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. Curr Pharm Des. 2014;20(24): Review. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol Sep;14(10): doi: /S (13) Epub 2013 Jul 22. Garassino M.C., Piva S, La Verde N., Spagnoletti I., Iorno V., Carbone C., Febbraro A., Bianchi A., Bramati A., Moretti A., Ganzinelli M., Marabese M., Gentili M:, Torri V., Farina G. Randomised phase II trial (NCT ) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013;8(4):e doi: /journal.pone Epub 2013 Apr 5. La Verde N, Piva S, Colombo F, Borgonovo K, Gramegna G, Girelli S, Dimaiuta M, Galfrascoli E, Battaglia E, Farina G. Lung infiltrates in cancer patients: differentiating metastases from bronchiolitis obliterans organizing pneumonia. Immunopharmacol Immunotoxicol Feb;35(1): doi: / Epub 2012 Oct 26. La Verde N, Moretti A, Bramati A, Bianchi F, Gherardi G, Piva S, Girelli S, Pedretti D, Farina G. Multiple myeloma with prostate involvement: a case report. J Clin Oncol Nov 1;30(31):e doi: /JCO Epub 2012 Sep 10. La Verde N, Bramati A, Girelli S, Piva S, Moretti A, Sburlati P, Mihali D, Farina G. Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report. Anticancer Drugs Aug;23(7): doi: /CAD.0b013e bbe. Lurati C, Riva M, Resega R, Mantica C, Garassino MC, Sburlati P, La Verde N, Cinquini M, Piva S, Mencacci C, Farina G. A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer Mar;20(3): doi: /s x. Epub 2011 Jan 22. Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, Muserra G, Farina G, Garassino MC; ORION Collaborative Group. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis Apr;43(4): doi: /j.dld Epub 2010 Dec 13. Review. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma Nov;49(11): Doi: / ABSTRACT, POSTER E REVIEW La Verde N, Dazzani C, Moretti A, Gamucci K, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Piva S, Farina G, Di Maio M. Acitvity of eribulin on skin metastases in breast cancer patients. J Clin Oncol 31: 2013 (suppl; abstr e12021) Piva S, Vitali M, Garassino MC. Targeted Therapy in Non-Small Cell Lung Cancer: an Update. Cancer Chemotherapy Reviews, 2012, Vol 7, No 3. La Verde N, Bramati A, Piva S, Dazzani MC, Girelli S, Moretti A, Mihali D, Dimaiuta M, Pinto A e Farina G. A prospective mono-institutional study on the impact of a systematic prevention program on the incidence and

4 outcomeof osteonecrosis of the jaw (ONJ) in patients (pts) treated with biphosphonates (B) for bone metastases. Ann Oncology (2012), 23 (s9):1585p. Bramati A, Piva S, La Verde N, Girelli S, Cobelli S, Moretti A, Mantica C, Pinto A, Rovej R, Farina G. A long term mono-institutional follow-up of the incidence of osteonecrosis of the jaw (ONJ) with a prevention program in patients treated with biphosphonates (B) for bone metastases. Tumori 2012, vol 13, n 3, abs S57. La Verde N, Bramati a, Bianchi A, Galfrascoli E, Sburlati P, Garassino M, Piva S, Torri V, Cinquini M, Farina G. Efficacy of biologic agents (BA) in metastatic, triple-negative breast cancer (TNBC): A systematic review. J Clin Oncol 29: 2011 (suppl; abstr e11587). Piva S, Garassino MC. Novità nel trattamento dei tumori polmonari non microcitomi. Medical Oncology Progress and Perspectives, Update 38, Piva S, Garassino MC. Trattamento del carcinoma renale metastatico nel paziente dializzato. Esperienze cliniche nel trattamento del carcinoma a cellule renali. Medicom, Springer-Verlag, Piva S, Mantica C, La Verde N, Bramati A, Mora M, Causarano I, Lacaita G, Piazza E, Martini C, Farina G. A new organizational model in the city of Milan has improved the best setting of care for terminal patients. Ann Oncol (2010) 21(s8): viii343. Cinquini M, Martelli O, Rossi A, Piva S, Farina G, Torri V. Meta-analysis of published randomized clinical trials (RCTS) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIS) regimens for extensive-disease small-cell lung cancer (ED-SCLC). Ann Oncol (2010) 21(s8): viii150. Bramati A, Girelli S, Garassino MC, Piva S, La Verde N, Sburlati P, Moretti A, Bianchi A, Celso B, Farina G. Sunitinib-related psoriasis remission in patients affected by advanced clear cell renal cell carcinoma (RCC). Ann Oncol (2010) 21(s8): viii398. Bramati A, Garassino M, Cinquini M, Collovà E, Sburlati P, Califano R, La Verde N, Piva S, Farina G, Moretti A, Zucali P. Second-line chemotherapy for malignant pleural mesothelioma: results from a multicenter retrospective analysis. Abstract 1023, ICACT Piva S, Spina F, Farina L, Dodero A, Milani R, Frungillo N, Morelli M, Montefusco V. Immune mediated cytopenia after reduced intensity allogeneic stem cell transplantation. Haematologica 2009; 94(s4): Montefusco V, Spina F, Galassi M, Capone F, Farina L, Dodero A, Piva S, Morelli M, Ascani L, Corradini P. Preliminary results of topical menthol for Bortezomib induced peripheral neuropathy. Haematologica 2009; 94(s4):89. Spina F, Farina L, Montefusco V, Carniti C, Morelli M, Piva S, Corradini P. Rituximab and donor lymphocyte infusions: an effective salvage treatment for lymphoma patients relapsed after reduced intensità allogeneic stem cell transplantation. Haematologica 2009; 94(s4): Montefusco V, Spina F, Farina L, Dodero A, Milani R, Frungillo N, Morelli M, Piva S, Corradini P. Autologous stem cell transplantation in old multiple myeloma patients. Haematologica 2009; 94(s4): Spina F, Farina L, Montefusco V, Carniti C, Piva S, Morelli M, Corradini P. Efficacy of rituximab and donor lymphocyte infusions as salvage treatment in lymphoma patients relapsed after reduced intensity allogeneic stem cell transplantation. Haematologica 2009; 94(s2):61. Dalu D, Cattaneo MT, Piazza E, Piva S, Gambaro A, Tosca N, Gabris A, Filipazzi V, Esani G, Ferrario S, Somma L, Sarnataro C, Zambelli S, Damiani E. Clinical use of the serum marker HER 2/neu in patients with breast cancer. Annals of Oncology 2007; vol 18, supp 11. Milani R, Dodero A, Piva S, Testi A, Tarella C, Bandini G, Bernardi M, Gianni AM, Leoni P, Olivieri A, Corradini P. Long-term outcome after reduced-intensity conditioning allogeneic transplantation in therapyrelated myelodisplastc syndromes and acute myeloid leukemias. Haematologica 2007; 92(s1):

5 Piazza E, Schiavello E, Gambi V, Fasola C, Piva S, Cattaneo MT, Filipazzi V, Dalla Vecchia L, Gambaro A, Tosca N, Esani G, Ferrario S, Isabella L, Damiani E. Use of NT probnp as a marker of cardio toxicity during antiblastic chemotherapy. Annals of Oncology 2005; vol 16, supp 7. Lucini D, Pizzinelli P, Malacarne C, Piva S, Pace F, Pagani M. Qualità percepita ed efficacia della didattica frontale in medicina intrna: risultati preliminari e proposta di modello valutativo. 105 Congresso Nazionale della Società Italiana di Medicina nterna, ottobre 2004, Palermo